Autologous CAR T-cell therapy or Chimeric Antigen Receptor Cell is a type of immunotherapy in which researchers collect a patient’s T-cells — immune cells with anti-cancer activity — and engineer them to recognize and eliminate cancer cells. The treated cells are then returned to the patient to fight the tumor. These are called induced pleura patent cells.
But first-generation autologous CAR T-cell therapies required researchers to collect blood samples from patients to isolate their own T-cells, making the process extremely slow and expensive. The iPSC-derived CAR T-cell product (iCART) is a new type of CAR T-cell therapy based on the use of a cell bank of identical master IPS cells — fully matured cells that can be reprogrammed back to a stem cell state, where they are able to grow into any type of cell. Unlike a patient’s own T-cells, IPS cells can be an immediate and renewable…
